Yervoy ipilimumab regulatory update

FDA approved an sBLA from Bristol-Myers Squibb for Yervoy ipilimumab as adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of >1 mm who have und...